Johnson & Johnson (JNJ) call put ratio 1.7 calls to 1 put options update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Johnson & Johnson (JNJ) PT Lowered to $175 at RBC Capital
April 17, 2024 7:05 AM EDTRBC Capital analyst Shagun Singh lowered the price target on Johnson & Johnson (NYSE: JNJ) to $175.00 (from $181.00) while maintaining a Outperform rating.
The analyst comments "JNJ's stock traded modestly lower post-Q1'24, where it delivered inline sales and EPS beat. JNJ tightened FY24 operational guidance... More
Johnson & Johnson (JNJ) PT Lowered to $170 at BofA Securities
April 17, 2024 5:12 AM EDTBofA Securities analyst Geoff Meacham lowered the price target on Johnson & Johnson (NYSE: JNJ) to $170.00 (from $180.00) while maintaining a Neutral rating.
The analyst comments "JNJ shares traded down today (-2.0%; DRG -0.3%) despite a solid 1Q and reported guidance midpoint unchanged, which we suspect was due to disappointing Carvykti sales (-1% q/q) and Vision business (-3% y/y).... More
Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance
April 16, 2024 6:45 AM EDTJohnson & Johnson (NYSE: JNJ) reported mixed financial results for the first quarter of 2024, with adjusted earnings per share (EPS) slightly surpassing analyst expectations, while revenue fell marginally short of estimates. The healthcare giant posted an adjusted EPS of $2.71, which was $0.07 higher than the consensus estimate of $2.64. However, quarterly revenue was a hair's breadth away from consensus, coming in at $21.38 billion against... More
